WilmerHale represented the underwriters in the public offering by Candel Therapeutics, Inc. of 12,000,001 shares of common stock, reflecting the full exercise of the underwriters’ option to purchase 2,000,000 additional shares, and 3,333,333 pre-funded warrants to purchase shares of common stock. Candel Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer. The offering priced on December 12, 2024 and closed on December 16, 2024.  Candel received approximately $92 million in gross proceeds, before deducting underwriting discounts and commissions and other offering expenses.  

The team consisted of Lisa Firenze, Scott Lunin, Leigh Krafchek, Erin Bruynell Gallagher and Whitley Horning, with assistance from Bruce Manheim on regulatory matters and Barish Ozdamar Ph.D. on intellectual property matters.